Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420
MONTREAL, A8 H4M 2X6
Founded
2003
Number of Employees
47
Website
http://www.milestonepharma.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)